Erdafitinib inhibits the tumorigenicity of MDA-MB-231 triple-negative breast cancer cells by inducing TRIM25/ubiquitin-dependent degradation of FGFR4

Abstract Triple-negative breast cancer (TNBC) is the most malignant subtype of breast cancer (BC), characterized by limited treatment options and poor clinical outcomes. Aberrant FGFR signaling has been implicated in TNBC; however, the therapeutic potential of targeting FGFRs for TNBC treatment rema...

詳細記述

書誌詳細

主要な著者:	Qing Luo, Li Zhang, Yue Hao, Chunwei Xu, Xiaojia Wang, Zhen Jia, Xiandong Xie, Zhihong Huang, Xiaomin Gao, Yu Chen, Xue Zhu, Jing Fang, Ke Wang, Yongxiang Yin
フォーマット:	Artigo
言語:	Inglês
出版事項:	BMC 2025-07-01
シリーズ:	Breast Cancer Research
主題:	TNBC Erdafitinib FGFR1/4 TRIM25 Ubiquitination Biomarker
オンライン･アクセス:	https://doi.org/10.1186/s13058-025-02086-7
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!